Nilotinib 641571-10-0
Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor. It inhibits BCR-ABL.
Uses
It was approved as Tasigna in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after five months of treatment. The drug carries a black box warning for possible heart complications.
| Systematic (IUPAC) name: | 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)- 5-(trifluoromethyl)phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino]benzamide |
|---|---|
| Nilotinib CAS number: | 641571-10-0 |
| ATC code: | L01XE08 |
| PubChem: | 644241 |
| DrugBank: | |
| Formula: | C28H22N7O1 |
| Molecular mass: | 565.98 g/mol |
| Nilotinib Assay/Purity: | Typically NLT 98% |
